Circulating oxidized low-density lipoprotein is an independent predictor for cardiac event in patients with coronary artery disease

被引:111
作者
Shimada, K [1 ]
Mokuno, H [1 ]
Matsunaga, E [1 ]
Miyazaki, T [1 ]
Sumiyoshi, K [1 ]
Miyauchi, K [1 ]
Daida, H [1 ]
机构
[1] Juntendo Univ, Sch Med, Dept Cardiol, Bunkyo Ku, Tokyo 1138421, Japan
关键词
oxidized low-density lipoprotein; cardiac event; coronary artery disease; enzyme-linked immunosorbent assay;
D O I
10.1016/j.atherosclerosis.2004.01.029
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Oxidized low-density lipoprotein (oxLDL) plays a crucial role in the development of atherosclerosis, however, the predictive value of circulating oxLDL for cardiac events (CE) in patients with coronary artery disease (CAD) has remained poorly understood. We prospectively studied 238 consecutive patients with documented CAD for up to 52 months until the occurrence of one of the following cardiac events: cardiac death, nonfatal myocardial infarction (MI), and refractory angina requiring revascularization. The plasma levels of oxLDL were measured by an enzyme-linked immunosorbent assay (ELISA) using the monoclonal antibody, DLH3. The levels of circulating oxLDL were significantly higher in patients with CE than in patients without CE (median 20.3 U/mI versus 17.6 U/ml, P = 0.002). Multivariate Cox models showed that higher level of oxLDL was an independent predictor of developing CE. The adjusted hazard ratios for CE were 3.15 (95% CI 1.47-6.76, P = 0.003) times higher in patients with the highest quartile of oxLDL levels and 1.88 (95% CI 0.90-3.95, P = 0.09) times higher in patients with the third quartile than in those within the lowest quartile. Thus, measurement of circulating oxLDL may be helpful in the assessment of future CE in patients with CAD. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:343 / 347
页数:5
相关论文
共 20 条
  • [1] PRESENCE OF A MODIFIED LOW-DENSITY LIPOPROTEIN IN HUMANS
    AVOGARO, P
    BON, GB
    CAZZOLATO, G
    [J]. ARTERIOSCLEROSIS, 1988, 8 (01): : 79 - 87
  • [2] MINIMALLY MODIFIED LOW-DENSITY-LIPOPROTEIN STIMULATES MONOCYTE ENDOTHELIAL INTERACTIONS
    BERLINER, JA
    TERRITO, MC
    SEVANIAN, A
    RAMIN, S
    KIM, JA
    BAMSHAD, B
    ESTERSON, M
    FOGELMAN, AM
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1990, 85 (04) : 1260 - 1266
  • [3] Pathophysiological role of oxidized low-density lipoprotein in plaque instability in coronary artery diseases
    Ehara, S
    Ueda, M
    Naruko, T
    Haze, K
    Matsuo, T
    Ogami, M
    Ikura, Y
    Itabe, H
    Komatsu, R
    Yoshiyama, M
    Takeuchi, K
    Yoshikawa, J
    [J]. JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2002, 16 (01) : 60 - 64
  • [4] Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes
    Ehara, S
    Ueda, M
    Naruko, T
    Haze, K
    Itoh, A
    Otsuka, M
    Komatsu, R
    Matsuo, T
    Itabe, H
    Takano, T
    Tsukamoto, Y
    Yoshiyama, M
    Takeuchi, K
    Yoshikawa, J
    Becker, AE
    [J]. CIRCULATION, 2001, 103 (15) : 1955 - 1960
  • [5] Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease
    Holvoet, P
    Vanhaecke, J
    Janssens, S
    Van de Werf, F
    Collen, D
    [J]. CIRCULATION, 1998, 98 (15) : 1487 - 1494
  • [6] Oxidized low density lipoprotein is a prognostic marker of transplant-associated coronary artery disease
    Holvoet, P
    Van Cleemput, J
    Collen, D
    Vanhaecke, J
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (03) : 698 - 702
  • [7] Holvoet P, 1996, THROMB HAEMOSTASIS, V76, P663
  • [8] Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease
    Holvoet, P
    Mertens, A
    Verhamme, P
    Bogaerts, K
    Beyens, G
    Verhaeghe, R
    Collen, D
    Muls, E
    Van de Werf, F
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2001, 21 (05) : 844 - 848
  • [9] Oxidized low-density lipoproteins: What is understood and what remains to be clarified
    Itabe, H
    [J]. BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2003, 26 (01) : 1 - 9
  • [10] ITABE H, 1994, J BIOL CHEM, V269, P15274